๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Nutritional, dietary, and hormonal treatments for individuals with mental retardation and developmental disabilities

โœ Scribed by Ellis, Cynthia R. ;Singh, Nirbhay N. ;Ruane, Amy L.


Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
137 KB
Volume
5
Category
Article
ISSN
1080-4013

No coin nor oath required. For personal study only.

โœฆ Synopsis


Nutritional, dietary, and hormonal approaches to producing behavioral, emotional, and cognitive changes in individuals with mental retardation and developmental disabilities (MRDD) flourished in the 1970s and 1980s. Although an occasional article is still published, there was little serious research activity in recent years until interest in secretin as a potential treatment for autism stimulated the new surge of research currently under way. We briefly discuss the general findings of the effects of various nutritional, dietary, and hormonal approaches in the treatment of individuals with MRDD. We will not review the literature dealing with the nutritional status of individuals with MRDD. We recognize that some of these individuals have disorders that may compromise their nutritional well-being (e.g., maple syrup urine disease, phenylketonuria, and galactosemia) and, therefore, require specific nutritional interventions. Our focus is on nutritional and dietary approaches that are intended to enhance cognitive ability or treat behavioral and emotional problems in individuals with MRDD. We also discuss use of the hormones, melatonin and secretin, in this population. Overall, we found the quality of the research on vitamins, minerals, hormones, and dietary treatments for individuals with MRDD to be overwhelmingly anecdotal and poorly controlled, and the outcomes not strongly supportive of their efficacy.

1999 Wiley-Liss, Inc.


๐Ÿ“œ SIMILAR VOLUMES


Measuring side effects of psychopharmaco
โœ Kalachnik, John E. ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 173 KB ๐Ÿ‘ 2 views

To various degrees, psychopharmacologic medications are associated with side effects. Despite improvements in newer psychopharmacologic medication, monitoring for side effects remains important for individuals with mental retardation and developmental disabilities for a number of reasons, of which p

Drug-behavior interactions in persons wi
โœ Napolitano, Deborah A. ;Jack, Susan L. ;Sheldon, Jan B. ;Williams, Dean C. ;McAd ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 174 KB ๐Ÿ‘ 2 views

Treatment for aberrant behavior in persons diagnosed with developmental disabilities typically involves either behavioral interventions or medication. Often, the treatment is a combination of the two. Schroeder and coworkers Adv Learn Behav Disabil 2:179-225) outlined criteria for the evaluation of